Orient Pharma Co., Ltd. (TPEX:4166)

Market Cap	6.49B
Revenue (ttm)	1.28B
Net Income (ttm)	127.99M
Shares Out	243.04M
EPS (ttm)	0.57
PE Ratio	47.02
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,006
Average Volume	270,257
Open	26.60
Previous Close	26.70
Day's Range	26.60 - 26.80
52-Week Range	22.30 - 40.20
Beta	0.08
RSI	52.60
Earnings Date	Mar 20, 2026

About Orient Pharma

Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 173
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4166

Financial Performance

In 2024, Orient Pharma's revenue was 1.22 billion, an increase of 37.41% compared to the previous year's 889.91 million. Earnings were 107.37 million, an increase of 381.76%.